Machens Andreas, Lorenz Kerstin, Dralle Henning
Department of General, Visceral, and Vascular Surgery, Martin Luther University Halle-Wittenberg, D-06097 Halle (Saale), Germany.
J Clin Endocrinol Metab. 2014 Feb;99(2):E286-92. doi: 10.1210/jc.2013-3343. Epub 2013 Jan 1.
There is no histopathological or radiological information on the natural course of tumor growth and lymph node metastasis in medullary thyroid cancer (MTC).
This investigation aimed at determining annual rates of tumor growth and lymph node metastasis in hereditary MTC at the surgical pathology level.
This was a retrospective analysis.
The setting was a tertiary referral center.
Included were 172 carriers of American Thyroid Association (ATA) class C (95 patients) and class A rearranged during transfection (RET) mutations (77 patients) with MTC.
The intervention was compartment-oriented surgery.
Comparisons of means between index and nonindex patients yielded incremental primary tumor diameter and incremental number of lymph node metastases, which were divided by incremental patient age at tissue diagnosis.
Annual primary tumor growth was 0.4-0.5 mm in node-negative carriers of ATA class A and C mutations. In node-positive carriers, annual primary tumor growth was 2.6 mm (ATA class C mutations) and 1.2 mm (ATA class A mutations), more than 6-fold (2.6 vs 0.4 mm) and more than 2-fold greater (1.2 vs 0.5 mm) than in their node-negative peers. Node-positive carriers revealed an annual rate of lymph node metastasis of 0.6-0.7 nodes independent of ATA class.
Small MTCs may take longer than 10 years to become big enough to visualize on imaging. These slow growth rates highlight the importance of following up on patients for very long time periods to uncover at least some tumoral sources of persistent calcitonin production.
关于甲状腺髓样癌(MTC)肿瘤生长和淋巴结转移的自然病程,目前尚无组织病理学或放射学信息。
本研究旨在确定遗传性MTC在外科病理学水平上的肿瘤年生长率和淋巴结转移率。
这是一项回顾性分析。
研究地点为三级转诊中心。
纳入了172例美国甲状腺协会(ATA)C类(95例患者)和A类转染重排(RET)突变(77例患者)的MTC携带者。
干预措施为分区手术。
比较索引患者和非索引患者的均值,得出原发性肿瘤直径增量和淋巴结转移数量增量,再除以组织诊断时患者的年龄增量。
ATA A类和C类突变的淋巴结阴性携带者的原发性肿瘤年生长率为0.5毫米。淋巴结阳性携带者中,原发性肿瘤年生长率为2.6毫米(ATA C类突变)和1.2毫米(ATA A类突变),分别比其淋巴结阴性的同龄人高出6倍多(2.6对0.4毫米)和2倍多(1.2对0.5毫米)。淋巴结阳性携带者的淋巴结转移年发生率为0.6至0.7个,与ATA类别无关。
小型MTC可能需要超过10年的时间才能长大到在影像学上可见。这些缓慢的生长速度凸显了对患者进行长期随访以发现至少一些持续产生降钙素的肿瘤来源的重要性。